Search

Your search keyword '"Alcaide, Julia"' showing total 40 results

Search Constraints

Start Over You searched for: Author "Alcaide, Julia" Remove constraint Author: "Alcaide, Julia"
40 results on '"Alcaide, Julia"'

Search Results

2. Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?

5. The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1+ tumour-infiltrating lymphocytes

6. Biological and prognostic differences between symptomatic colorectal carcinomas and those detected by screening

8. Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials

12. Influence of Diagnostic Delay on Survival Rates for Patients with Colorectal Cancer

13. Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).

15. Incidence of COVID-19 in outpatients with cancer receiving active treatment in the context of a pandemic: An Andalusian cohort study

18. The mutational load and a T-cell inflamed tumor phenotype identify ovarian cancer patients rendering tumor-reactive T cells from PD-1+ tumor-infiltrating lymphocytes

19. Clinical utility of comprehensive circulating tumor DNA (ctDNA) testing compared to standard-of-care (SoC) tissue testing in first-line (1L) metastatic colorectal cancer (mCRC) patients (pts).

21. Biological and prognostic differences between symptomatic colorectal carcinomas and those detected by screening

23. The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1+ tumour-infiltrating lymphocytes.

24. Outcomes of open versus laparoscopic surgery in patients with colon cancer

25. Metastases resection after FOLFIRI-aflibercept (FA) in oxaliplatin-refractory colorectal cancer patients (ORF-CRC).

27. Factors Associated with Prolonged Patient-Attributable Delay in the Diagnosis of Colorectal Cancer.

28. Efficacy and safety of aflibercept in metastatic colorectal cancer pretreated with bevacizumab: A report of five cases

30. Activity of aflibercept (Afli) in combination with FOLFIRI (F) for patients with metastatic colorectal cancer (mCRC) in a real-life setting in Spain: Final results of the retrospective study Named Patient Program.

31. Upfront vs deferred monoclonal antibodies in metastatic colorectal cancer: A target trial emulation using the GEMCAD 14-01 prospective cohort.

32. Avaliação da modulação autonômica cardíaca de cavalos submetidos à sessão submáxima de exercício em caminhador automático.

33. Guidelines for diagnosis, staging and treatment of metastatic colorectal cancer by Grupo Español Multidisciplinar en Cancer Digestivo (GEMCAD)

34. Preliminary data indicating the prevalence of secondary exocrine pancreatic insufficiency and impact of nutritional condition in gastrectomised patients

38. Validação do uso de frequencímetro para obtenção da variabilidade da frequência cardíaca em equinos submetidos a exercícios.

39. Efficacy and safety of aflibercept in metastatic colorectal cancer pretreated with bevacizumab: A report of five cases

40. Influence of Diagnostic Delay on Survival Rates for Patients with Colorectal Cancer.

Catalog

Books, media, physical & digital resources